{"id":"W2168108459","doi":"10.1016/s1470-2045(12)70379-0","title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1387,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal; BC Cancer Agency","funders":"Janssen Research and Development; UCLH Biomedical Research Centre","keywords":"Abiraterone acetate; Medicine; Placebo; Prednisone; Prostate cancer; Clinical endpoint; Interim analysis; Internal medicine; Enzalutamide; Docetaxel; Population; Oncology; Androgen deprivation therapy; Clinical trial; Cancer; Androgen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002663993,0.00190008,0.003537483,0.0006525494,0.0004670582,0.001228116,0.0008827086,0.001588456,0.00469738],"category_scores_gemma":[0.002572815,0.0006595561,0.003152893,0.0006870211,0.001525489,0.0009747409,0.0004144125,0.002915118,0.0008974103],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007387291,"about_ca_system_score_gemma":0.001245197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002008203,"about_ca_topic_score_gemma":0.00422779,"domain_scores_codex":[0.998769,0.0007841157,0.00007981049,0.0001174907,0.0001205775,0.0001290341],"domain_scores_gemma":[0.9981489,0.0007056774,0.0003927962,0.0002237041,0.00009717358,0.0004317415],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.98699,0.001202461,0.0003298945,0.0004444844,0.0009753189,0.00002272708,0.00003316144,0.0002644972,0.001508781,0.0000430531,0.0003145562,0.00787115],"study_design_scores_gemma":[0.9526424,0.04186323,0.00306597,0.0000340606,0.001113774,0.00004727475,0.00002384562,0.0002823474,0.0002763102,0.0001749799,0.0004522688,0.00002364341],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9799986,0.01212848,0.0009932175,0.0005739984,0.000557118,0.001559082,0.001577385,0.0002240476,0.002388019],"genre_scores_gemma":[0.9889075,0.00486267,0.0008173855,0.0005930887,0.0004681344,0.0009306689,0.001055281,0.0000400379,0.002325229],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00469738,"threshold_uncertainty_score":0.01571429,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.187337688920738,"score_gpt":0.4545089135261337,"score_spread":0.2671712246053957,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}